The Food and Drug Administration rejected AcelRx Pharmaceuticals Inc.'s (Nasdaq: ACRX) acute pain treatment Dsuvia in its present form. The stock price collapsed $3.20 to close at $2.15.
AcelRx Pharmaceuticals' Dsuvia rejected
October 12, 2017 at 16:54 PM EDT
